PaulaM.FracassoMDPhD, FACP

Breast Cancer, Gynecologic Cancer, Hematologic Oncology

Professor of Medicine and Gynecologic Oncology, Virginia Commonwealth University School of Medicine

Dr. Fracasso is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
VCU Massey Cancer Center
401 College Street
Richmond, VA 23298
Phone+1 804-628-0660

Board-certified medical oncologist, academic leader, and pharmaceutical executive with significant experience building cancer centers in academic medical centers and developing oncology drugs in biopharmaceutical companies. Expertise in preclinical, translational and clinical development of cellular and immuno-oncology therapies including clinical trial design, regulatory strategies, translational medicine, biomarkers/companion diagnostics, pharmacology, and medical oncology for the delivery of cutting-edge patient care.

Alpha Omega Alpha
Phi Beta Kappa
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

PubMed

49 citations
A Phase II study of Dovitinib in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Patrick M. Dillon, Gina R. Petroni, Bethany J. Horton, Christopher A. Moskaluk, Paula M. Fracasso
Clinical Cancer Research. 2017-08-01
9 citations
Phase I study of rubitecan and gemcitabine in patients with advanced malignancies
Paula M. Fracasso, Janet S. Rader, Ramaswamy Govindan, Thomas J. Herzog, Matthew A. Arquette
Annals of Oncology. 2002-11-01
34 citations
Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study
Warner K. Huh, William E. Brady, Paula M. Fracasso, Don S. Dizon, Matthew A. Powell
Gynecologic Oncology. 2020-09-01

The Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) Program: Innovative, High-Throughput Clinical Screening of ImmunotherapiesOctober 2018

Providing HopeSeptember 30th, 2024
Paula Fracasso Joins VCU Massey Cancer Center to Lead the Cancer Service LineSeptember 14th, 2022
Global Cancer Rates in People 50 and Younger on the Rise, Study FindsSeptember 7th, 2022
Join now to see all

An Exploratory Study Of UCN-01 And Irinotecan In Advanced Triple Negative BreastNational Cancer Institute2007–2008
Overcoming Barriers To Early Phase Clinical TrialsNational Cancer Institute2003–2004
Oral SDZ PSC 833 And Intravenous Paclitaxel In Advanced CancerNational Center For Research Resources1998–1999
Taxol And SDZ PSC 833 In Patients With Refractory MalignanciesNational Center For Research Resources1997–1999
Oral SDZ PSC 833 And Intravenous Paclitaxel In Advance CancerNational Center For Research Resources1996
Comparison Of CDNA Transcripts Of MDR Genes In The MouseNational Cancer Institute1990–1991
Comparison Of CDNA Transcripts Of MDR Genes In The MouseNational Cancer Institute1988